NEW YORK (GenomeWeb News) – Sigma-Aldrich today said that its BioReliance business has signed an agreement to acquire colonies and cell lines for toxicology testing from Agilent Technologies.

The deal covers colonies required for Agilent's Big Blue transgenic rodent mutation assay, which are in vivo genetic toxicology assays that measure mutation frequency in tissue. BioReliance will now own the Big Blue mutation models and will be the exclusive supplier of testing services based on the model.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: human cytomegalovirus diversity, patterns of homologous recombination in E. coli, and more.

US lawmakers are considering eliminating the medical devices tax that is part of the Affordable Care Act.

Two research teams in China home in on a gene that gives rice a long, slender shape.

Marcia McNutt, the editor-in-chief of Science, has been nominated to become president of the US National Academy of Sciences.